Umbilical cord blood (UCB) has been an accepted source of hematopoietic stem cells (HSC) for transplantation for more than 30 years. Umbilical cord-derived stem cells are the youngest cells available for transfusion and yet their uptake lags behind bone marrow and peripheral blood-derived HSCs. Decreased engraftment rates and the low cell dose available for transplantation are limitations that are preventing umbilical cord blood-derived cells from reaching their full potential. While a handful of companies are now developing cord blood and tissue-derived cell therapeutics, it will likely take several years for these products to reach commercialization. [Read more…]
Hematopoietic Stem Cells (HSCs)
Are you or a loved on suffering from arthritis, multiple sclerosis (MS), COPD, Alzheimer’s disease, asthma, or other chronic condition? If so, how do you find a stem cell clinical trial?
This article provides the answers, including links to find a clinical trials near you, as well as links to clinical trials for specific conditions.
Many experts have spoken about the power of stem cells and their ability to alter the field of healthcare forever, including these top stem cell quotes of all-time. With exponential progress occurring in the field, stem cells are ushering in an age of regenerative medicine that will transform healthcare in ways that are now inconceivable.
In coming decades, stem cells will be reversing diseases ranging from Alzheimer’s to autism, re-growing organs and tissues, and potentially allowing the first humans to reach the age of 200.
Some exciting advances with stem cells include these “science fictions” that have become “science facts”: [Read more…]
The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]
ReeLabs is an important cord blood banking brand within India. Cord blood banking in this region is of historic importance, because India has an astounding population of 1.4 billion. Representing 18% of the global population, nearly one-in-five people lives in India, placing it head-to-head with China as the world’s most populous country. India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
If you’re involved with cord blood banking, then you need to pay attention to this enormous consumer market.
In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.